Literature DB >> 20373263

siRNA-based topical microbicides targeting sexually transmitted infections.

Joseph A Katakowski1, Deborah Palliser.   

Abstract

Sexually transmitted infections (STIs) are a major cause of morbidity and mortality worldwide. Although a vaccine is available for HPV, no effective vaccines exist for the HIV-1 and HSV-2 viral pathogens, and there are no cures for these infections. Furthermore, recent setbacks in clinical trials, such as the failure of the STEP trial to prevent HIV-1 infection, have emphasized the need to develop alternative approaches to interrupt the transmission of these pathogens. One alternative strategy is represented by the use of topically applied microbicides, and such agents are being developed against various viruses. RNAi-based microbicides have recently been demonstrated to prevent HSV-2 transmission, and may be useful for targeting multiple STIs. In this review, microbicides that are under development for the prevention of STIs are described, with a focus on topically applied microbicidal siRNAs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373263      PMCID: PMC3282625     

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  79 in total

1.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation.

Authors:  Marjorie Robbins; Adam Judge; Ellen Ambegia; Catherine Choi; Ed Yaworski; Lorne Palmer; Kevin McClintock; Ian MacLachlan
Journal:  Hum Gene Ther       Date:  2008-10       Impact factor: 5.695

2.  Human immunodeficiency virus type 1 escape from RNA interference.

Authors:  Daniel Boden; Oliver Pusch; Frederick Lee; Lynne Tucker; Bharat Ramratnam
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 3.  siRNA and innate immunity.

Authors:  Marjorie Robbins; Adam Judge; Ian MacLachlan
Journal:  Oligonucleotides       Date:  2009-06

4.  Glycerol monolaurate prevents mucosal SIV transmission.

Authors:  Qingsheng Li; Jacob D Estes; Patrick M Schlievert; Lijie Duan; Amanda J Brosnahan; Peter J Southern; Cavan S Reilly; Marnie L Peterson; Nancy Schultz-Darken; Kevin G Brunner; Karla R Nephew; Stefan Pambuccian; Jeffrey D Lifson; John V Carlis; Ashley T Haase
Journal:  Nature       Date:  2009-03-04       Impact factor: 49.962

5.  Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques.

Authors:  Dawn M Dudley; Jennifer L Wentzel; Matthew S Lalonde; Ronald S Veazey; Eric J Arts
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.

Authors:  Yven Van Herrewege; Jo Michiels; Jens Van Roey; Katrien Fransen; Luc Kestens; Jan Balzarini; Paul Lewi; Guido Vanham; Paul Janssen
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 7.  CCR5 monoclonal antibodies for HIV-1 therapy.

Authors:  William C Olson; Jeffrey M Jacobson
Journal:  Curr Opin HIV AIDS       Date:  2009-03       Impact factor: 4.283

8.  Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs.

Authors:  Aly A Khan; Doron Betel; Martin L Miller; Chris Sander; Christina S Leslie; Debora S Marks
Journal:  Nat Biotechnol       Date:  2009-06       Impact factor: 54.908

9.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.

Authors:  Jiehua Zhou; Piotr Swiderski; Haitang Li; Jane Zhang; C Preston Neff; Ramesh Akkina; John J Rossi
Journal:  Nucleic Acids Res       Date:  2009-03-21       Impact factor: 16.971

10.  Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA.

Authors:  Kim A Woodrow; Yen Cu; Carmen J Booth; Jennifer K Saucier-Sawyer; Monica J Wood; W Mark Saltzman
Journal:  Nat Mater       Date:  2009-05-03       Impact factor: 43.841

View more
  7 in total

Review 1.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 2.  Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.

Authors:  Jill M Steinbach
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

3.  Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.

Authors:  Michael D Moore; Jonathan Cookson; Veronica K Coventry; Brian Sproat; Lorna Rabe; Ross D Cranston; Ian McGowan; William James
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

4.  RNA interference approaches for treatment of HIV-1 infection.

Authors:  Maggie L Bobbin; John C Burnett; John J Rossi
Journal:  Genome Med       Date:  2015-05-28       Impact factor: 11.117

Review 5.  Development and application of ribonucleic acid therapy strategies against COVID-19.

Authors:  Lin Ning; Mujiexin Liu; Yushu Gou; Yue Yang; Bifang He; Jian Huang
Journal:  Int J Biol Sci       Date:  2022-08-01       Impact factor: 10.750

Review 6.  Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV.

Authors:  Lee Adam Wheeler
Journal:  Infect Dis Obstet Gynecol       Date:  2014-01-12

7.  Evaluation of short-interfering RNAs treatment in experimental rabies due to wild-type virus.

Authors:  Camila Michele Appolinario; Susan Dora Allendorf; Marina Gea Peres; Clovis Reynaldo Fonseca; Acacia Ferreira Vicente; João Marcelo Azevedo de Paula Antunes; José Carlos Figueiredo Pantoja; Jane Megid
Journal:  Braz J Infect Dis       Date:  2015-08-05       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.